Valencell has won a collaborative NIH award to integrate RPI's daysimetry technology into Valencell's Healthset® platform.  This new mobile device, called the "Dayset," will measure the user's circadian environment and characterize the user's physiological response to lighting conditions throughout their normal everyday lives.  The ultimate goal of this research is to develop a comfortable, wearable, therapeutic device for treating jet-lag, sleep disorders, breast cancer, and more. 

This collaborative research has been funded through the NIH Genes, Environment, and Health Initiative (GEI).

Valencell is one of 6 recipients of the Spring 2008 NC IDEA award.  Valencell will use these funds to complete the beta phase validation of proprietary Healthset^® technology for fitness and eHealth markets.  Clinical validation will be led by researchers at the Duke Center for Living.

Vital Signs - Telemetry: Less a New Market, More the Future of Patient Monitoring

The long-term goal of this Phase 1 NIEHS grant is to develop a noninvasive, low-profile, real-time, affordable personal environmental exposure monitor platform that is virtually unnoticed by the user for maximum performance and convenience. Novel devices grown and fabricated by collaborators at North Carolina State University will be evaluated for feasibility in monitoring airborne pollutants.

NSF STTR Phase I: Monolithic Multiwavelength Blue-to-IR LED for Biomedical Diagnostics (July 2007 - June 2008).